In recent developments, artificial neural networks (ANNs) have demonstrated their capability to predict reaction cross-sections based on experimental data. Specifically, for predicting (α,n) reaction cross-sections, we meticulously fine-tuned the neural network's performance by optimizing its parameters through the Levenberg-Marquardt algorithm. The effectiveness of this approach is corroborated by notable correlation coefficients; an R-value of 0.90928 for overall correlation, 0.98194 for validation, 0.99981 for testing, and 0.94116 for the comprehensive network prediction. We conducted a rigorous comparison between the results and theoretical computations derived from the TALYS 1.95 nuclear code to validate the predictive accuracy. The mean square error value for artificial neural network results is 7620.92, whereas for TALYS 1.95 calculations, it has been found to be 50,312.74. This comprehensive evaluation process validates the reliability of the ANN based on the Levenberg-Marquardt algorithm in approximating the reaction sections, thus demonstrating its potential for comprehensive investigations. These recent developments confirm the feasibility of using ANN models to gain insight into (α,n) reaction cross-sections.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apradiso.2023.111115 | DOI Listing |
Nat Med
January 2025
Google Research, Mountain View, CA, USA.
Large language models (LLMs) have shown promise in medical question answering, with Med-PaLM being the first to exceed a 'passing' score in United States Medical Licensing Examination style questions. However, challenges remain in long-form medical question answering and handling real-world workflows. Here, we present Med-PaLM 2, which bridges these gaps with a combination of base LLM improvements, medical domain fine-tuning and new strategies for improving reasoning and grounding through ensemble refinement and chain of retrieval.
View Article and Find Full Text PDFJ Control Release
September 2024
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China. Electronic address:
Targeted radionuclide therapy (TRT) is an effective treatment for tumors. Self-condensation strategies can enhance the retention of radionuclides in tumors and enhance the anti-tumor effect. Considering legumain is overexpressed in multiple types of human cancers, a I-labeled radiopharmaceutical ([I]MAAN) based on the self-condensation reaction between 2-cyanobenzothiazole (CBT) and cysteine (Cys) was developed by us recently for treating legumain-overexpressed tumors.
View Article and Find Full Text PDFWater Environ Res
January 2024
College of Urban Construction, Nanjing Tech University, Nanjing, China.
In this work, the transformation law of nitrogen in sediment-water system under different flow rates and wastewater concentrations were investigated in a simulated sewage pipeline system. Results showed that the different flow rates and wastewater concentrations in the pipeline caused differences in microbial community in sediments and nitrogen transformation. When the flow rate increased from 0.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
October 2023
Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.
Introduction: We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP).
Methods: This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52. Patients were randomised 2:1:1:1:2 to subcutaneous spesolimab 3000 mg to W4 then 600 mg every 4 weeks (q4w), spesolimab 3000 mg to W4 then 300 mg q4w, spesolimab 1500 mg to W4 then 600 mg q4w, spesolimab 1500 mg to W4, 300 mg q4w to W16 then 300 mg every 8 weeks (q8w), or placebo switching to spesolimab 600 mg q4w at W16.
Lancet HIV
August 2023
Université de Paris Cité, Paris, France; Département de Maladies Infectieuses, Hôpitaux Saint-Louis, Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France; INSERM UMR 944, Paris, France.
Background: Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults living with multidrug-resistant HIV-1 up to 52 weeks.
Methods: This ongoing, international, phase 2/3 trial at 42 sites included adults living with multidrug-resistant HIV-1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!